P450-BM3 Variants Broaden Substrate Range
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for P450-BM3 enzymes that exhibit high levels of enzymatic activity over a wide range of substrates, as existing P450s are limited in their ability to efficiently catalyze reactions with diverse organic compounds.
Innovation Solution
Development of recombinant cytochrome P450-BM3 variants with at least 90% sequence identity to specific polypeptide sequences, which exhibit improved activity on substrates such as loratadine, imatinib, and diclofenac, and the provision of isolated recombinant polynucleotide sequences, expression vectors, and host cells for producing these variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing P450-BM3 enzymes are used, then the enzyme structure is stable and well-defined, but the enzymatic activity over a wide range of substrates is limited
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid sequences at specific positions (e.g., positions 93, 297, 306, 324, 399) to create variants with improved substrate range. Multiple sequence variants are described with specific substitutions like A93S, V297I, L306M, F324L, and G399S that enhance enzymatic activity across diverse substrates while maintaining structural stability.
Solution Approach 2:
The patent achieves universality by engineering P450-BM3 variants that can catalyze reactions with multiple different substrate types including but not limited to loratadine, imatinib, gefitinib, and diclofenac. The engineered enzyme maintains a single structure while gaining multi-functional capability to process diverse organic compounds efficiently.
2Adaptability or versatility
If P450-BM3 variants with improved substrate range are developed, then versatility increases, but the complexity of enzyme production and characterization increases
Solution Approach 1:
The patent applies segmentation by providing separate polynucleotide sequences (SEQ ID NO:1, 3, 5, 7, 9, 11, 13, or 15) encoding different P450-BM3 variants, allowing independent production and characterization of each variant. The enzyme is further segmented into expressible forms with specific regulatory sequences and vector systems for controlled production in host cells.
Solution Approach 2:
The patent uses copying by providing recombinant polynucleotide sequences that can be replicated and expressed in host cells to produce the enzyme variants. The polynucleotides encoding the improved P450-BM3 variants can be copied and propagated through standard molecular biology techniques, enabling scalable production without increasing inherent enzyme complexity.
3Productivity
If recombinant P450-BM3 variants are produced in host cells, then enzyme quantity increases, but the difficulty of obtaining high-purity enzyme increases
Solution Approach 1:
The patent applies extraction by providing methods to isolate and purify the recombinant P450-BM3 variants from host cells. The enzyme can be extracted from inclusion bodies or soluble fractions and purified through chromatographic methods to achieve high purity levels suitable for biotechnological applications.
Solution Approach 2:
The patent uses intermediaries by incorporating regulatory sequences and vector elements that facilitate expression and purification. The polynucleotide sequences include elements that enable selective expression in host cells and provide handles for purification, acting as intermediaries between genetic material and pure enzyme product.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The improved P450-BM3 variants demonstrate enhanced enzymatic activity and broad substrate compatibility, achieving higher conversion rates and turnover numbers compared to parental sequences, making them suitable for various biotechnological applications.
Implementation Method 1
The cytochrome P450 monooxgenases (P450s) comprise a large group of widely-distributed heme enzymes that are ubiquitous in the natural world. Cytochrome P450-BM3 (P450-BM3), obtained from Bacillus megaterium catalyzes the NADPH-dependent hydroxylation of long-chain fatty acids, alcohols, and amides, as well as the epoxidation of unsaturated fatty acids
Implementation Method 2
the recombinant cytochrome P450-BM3 variants of the present invention oxidize at least three organic substrates. In some further embodiments, the recombinant cytochrome P450-BM3 variants oxidize at least one organic substrate selected from loratadine, imatinib, geftinib, and diclofenac
Data Source
AI summary
The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.